BlumJ.L., JonesS.E., BuzdarA.U.: Multicentric phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol, 17: 485–493, 1999.
2.
ReichardtP., von MinckwitzG., LuckH.: Capecitabine: the new standard in metastatic breast cancer failing anthracycline and taxane containing chemotherapy? Mature results of a large multicentre phase II trial. Eur J Cancer, 37: 191 (abst. 699), 2001.
3.
O'ShaughnessyJ., MilesD., VukeljaS.: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: a phase III trial results. J Clin Oncol, 20: 2812–2823, 2002.
4.
NabholtzJ., SennH.J., BezwodaW.R.: Prospective randomised trial of docetaxel vs mitomycin plus vinblastine in pz with MBC progressing despite previous anthracycline containing chemotherapy. J Clin Oncol, 17: 1413–1424, 1999.
5.
SjostromJ., BlomqvistC., MourisdenH.: Docetaxel compared with sequential methotrexate and fluorouracil in patients with ABC after antrhacycline failure. A randomised phase III study with crossover on progression by the SBG. Eur J Cancer, 35: 1194–1201, 1999.
6.
TonkinK., ScarfeA.G., KoskiS.: Preliminary results of a phase I/II study of weekly T combined with intermittent X for patients with anthracycline pretreated MBC. Proc ASCO, 20: abst 2016, 2001.
7.
NadellaP., ShapiroC., OttersonG.A.: Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol, 230: 2616–2623, 2002.
8.
ScarfeA.G., BondarD., TonkinK.: Interim results of a phase II study of weekly T combined with intermittent X for patients with anthracycline pretreated MBC. Proc ASCO, 21: abst 1984, 2002.
9.
ProcopioG., BajettaE., GattinoniL: Elderly patients with advanced breast cancer: safety and efficacy of capecitabine. Eur J Cancer, 5 (Suppl 1): S138 (abst 451), 2003.
10.
BajettaE., CarnaghiC., SommaL., StampinoCG: A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease. Tumori, 82: 450–452, 1996.
11.
Van CutsemE., TwelvesC., CassidyJ.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol, 19: 4097–4106, 2001.
12.
TwelvesC: Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Eur J Cancer, 38 (suppl 2): 15–20, 2002.
13.
Van CutsemE., TwelvesC., TaberneroJ.: Mature results of a multinational phase II trial of capecitabine + oxaliplatin (XELOX), an effective first line option for patients with metastatic colonrectal cancer. Proc ASCO, 22: abst 1023, 2003.
14.
GrotheyA., JordanK., KellnerO.: Capecitabine + irinotecan vs capecitabine + oxaliplatin as first line treatment of advanced colorectal cancer: updated results of randomised phase II trial. Eur J Cancer, 5 (Suppl 1): S90, 2003.
15.
NowackiM., KroningH., CervantesA.: Improved safety of capecitabine vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT phase III study). Eur J Cancer, 5 (Suppl. 1): S326 (abst 1089), 2003.
